Growth Metrics

Idexx Laboratories (IDXX) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Idexx Laboratories (IDXX) over the last 17 years, with Q3 2025 value amounting to $274.6 million.

  • Idexx Laboratories' Net Income towards Common Stockholders rose 1793.89% to $274.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 1860.76%. This contributed to the annual value of $887.9 million for FY2024, which is 506.78% up from last year.
  • Per Idexx Laboratories' latest filing, its Net Income towards Common Stockholders stood at $274.6 million for Q3 2025, which was up 1793.89% from $294.0 million recorded in Q2 2025.
  • Over the past 5 years, Idexx Laboratories' Net Income towards Common Stockholders peaked at $294.0 million during Q2 2025, and registered a low of $132.0 million during Q2 2022.
  • Over the past 5 years, Idexx Laboratories' median Net Income towards Common Stockholders value was $203.5 million (recorded in 2021), while the average stood at $208.8 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first surged by 8259.7% in 2021, then crashed by 3461.3% in 2022.
  • Idexx Laboratories' Net Income towards Common Stockholders (Quarter) stood at $162.8 million in 2021, then increased by 5.8% to $172.2 million in 2022, then grew by 12.96% to $194.5 million in 2023, then increased by 11.12% to $216.1 million in 2024, then increased by 27.05% to $274.6 million in 2025.
  • Its Net Income towards Common Stockholders was $274.6 million in Q3 2025, compared to $294.0 million in Q2 2025 and $242.7 million in Q1 2025.